IL245672B - Pyrimidopyrimidinones useful as wee-1 kinase inhibitors - Google Patents

Pyrimidopyrimidinones useful as wee-1 kinase inhibitors

Info

Publication number
IL245672B
IL245672B IL245672A IL24567216A IL245672B IL 245672 B IL245672 B IL 245672B IL 245672 A IL245672 A IL 245672A IL 24567216 A IL24567216 A IL 24567216A IL 245672 B IL245672 B IL 245672B
Authority
IL
Israel
Prior art keywords
pyrimidopyrimidinones
wee
kinase inhibitors
kinase
inhibitors
Prior art date
Application number
IL245672A
Other languages
English (en)
Hebrew (he)
Other versions
IL245672A0 (en
Original Assignee
Almac Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almac Discovery Ltd filed Critical Almac Discovery Ltd
Publication of IL245672A0 publication Critical patent/IL245672A0/en
Publication of IL245672B publication Critical patent/IL245672B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D475/00Heterocyclic compounds containing pteridine ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL245672A 2013-12-19 2016-05-17 Pyrimidopyrimidinones useful as wee-1 kinase inhibitors IL245672B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1322602.2A GB201322602D0 (en) 2013-12-19 2013-12-19 Pharmaceutical compounds
PCT/GB2014/053793 WO2015092431A1 (en) 2013-12-19 2014-12-19 Pyrimidopyrimidinones useful as wee-1 kinase inhibitors

Publications (2)

Publication Number Publication Date
IL245672A0 IL245672A0 (en) 2016-06-30
IL245672B true IL245672B (en) 2021-10-31

Family

ID=50071157

Family Applications (1)

Application Number Title Priority Date Filing Date
IL245672A IL245672B (en) 2013-12-19 2016-05-17 Pyrimidopyrimidinones useful as wee-1 kinase inhibitors

Country Status (28)

Country Link
US (1) US9850247B2 (enExample)
EP (1) EP3083625B1 (enExample)
JP (1) JP6437559B2 (enExample)
KR (1) KR102405462B1 (enExample)
CN (1) CN105829315B (enExample)
AU (1) AU2014369457B2 (enExample)
BR (1) BR112016014151B1 (enExample)
CA (1) CA2933755C (enExample)
CY (1) CY1120035T1 (enExample)
DK (1) DK3083625T3 (enExample)
ES (1) ES2650013T3 (enExample)
GB (1) GB201322602D0 (enExample)
HR (1) HRP20180080T1 (enExample)
HU (1) HUE037908T2 (enExample)
IL (1) IL245672B (enExample)
LT (1) LT3083625T (enExample)
MX (1) MX371108B (enExample)
NO (1) NO3083625T3 (enExample)
NZ (1) NZ720178A (enExample)
PL (1) PL3083625T3 (enExample)
PT (1) PT3083625T (enExample)
RS (1) RS56731B1 (enExample)
RU (1) RU2691105C1 (enExample)
SG (1) SG11201603814TA (enExample)
SI (1) SI3083625T1 (enExample)
SM (1) SMT201800020T1 (enExample)
WO (1) WO2015092431A1 (enExample)
ZA (1) ZA201603337B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108137593B (zh) * 2015-04-21 2021-01-05 上海交通大学医学院附属瑞金医院 蛋白激酶抑制剂的制备和用途
EP3368538B1 (en) * 2015-11-01 2021-09-01 The Regents of The University of Colorado, A Body Corporate Wee 1 kinase inhibitors and methods of making and using the same
CN109906227B (zh) * 2016-11-16 2022-03-11 上海瑛派药业有限公司 8,9-二氢咪唑[1,2-a]嘧啶并[5,4-e]嘧啶-5(6H)-酮类化合物
EP3564232B1 (en) 2016-12-27 2022-01-26 Riken Bmp-signal-inhibiting compound
JP6717457B2 (ja) 2017-01-23 2020-07-01 シージャーズォアン サガシティ ニュー ドラッグ デベロップメント カンパニー リミテッド Wee1阻害剤としての1,2−ジヒドロ−3H−ピラゾロ[3,4−d]ピリミジン−3−オン誘導体
GB201703881D0 (en) 2017-03-10 2017-04-26 Almac Discovery Ltd Pharmaceutical compounds
AU2018243667A1 (en) 2017-03-31 2019-10-17 Seagen Inc. Combinations of Chk1- and Wee1 - inhibitors
WO2019011228A1 (zh) * 2017-07-10 2019-01-17 上海瑛派药业有限公司 咪唑并[1,2-b]嘧啶并[4,5-d]哒嗪-5(6H)-酮类化合物及其应用
CN109422754A (zh) * 2017-08-24 2019-03-05 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
AU2018347307A1 (en) 2017-10-09 2020-04-23 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
EP3694861A4 (en) 2017-10-09 2021-05-19 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND USES THEREOF
SI3712150T1 (sl) 2017-11-01 2024-09-30 Wuxi Biocity Biopharmaceutics Co., Ltd. Makrociklična spojina, ki deluje kot zaviralec WEE1 in njene uporabe
AU2019227823B2 (en) * 2018-02-28 2024-12-12 The Regents Of The University Of Colorado, A Body Corporate WEE1 kinase inhibitors and methods of treating cancer using the same
WO2020063788A1 (zh) * 2018-09-27 2020-04-02 贝达药业股份有限公司 Fgfr4抑制剂及其应用
EP3875460A4 (en) 2018-10-26 2022-07-20 Wuxi Biocity Biopharmaceutics Co., Ltd. PYRIMIDINDOPYRAZOLONE DERIVATIVE AS WEE1 INHIBITOR AND USE THEREOF
AU2019413360B2 (en) 2018-12-28 2025-05-22 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
JP2022528047A (ja) 2019-03-22 2022-06-08 ショウヤオ ホールディングス(ベイジン) カンパニー, リミテッド Wee1阻害剤、その製造および用途
WO2020210383A1 (en) * 2019-04-09 2020-10-15 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
WO2020210377A1 (en) * 2019-04-09 2020-10-15 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
EP3952877A4 (en) 2019-04-09 2022-12-14 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND THEIR USES
ES2984617T3 (es) 2019-04-30 2024-10-30 Wuxi Biocity Biopharmaceutics Co Ltd Forma de cristal del compuesto inhibidor de Wee1 y su uso
CN112142763B (zh) * 2019-06-28 2024-01-26 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
CN115698006B (zh) 2020-06-17 2024-03-29 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的吡唑并[3,4-d]嘧啶-3-酮衍生物
WO2022072336A1 (en) * 2020-10-01 2022-04-07 University Of Washington Drug-like molecules and methods for the therapeutic targeting of microrna-21
CA3201152A1 (en) * 2020-12-18 2022-06-23 Xiaoyang Dong Nitrogen containing 2,3-dihydroquinazolinone compounds as nav1.8 inhibitors
JP2024502231A (ja) * 2020-12-18 2024-01-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Nav1.8電位依存性ナトリウムチャネルを阻害するためおよびNav1.8介在疾患を治療するために有用な化学化合物
CA3214894A1 (en) 2021-04-30 2022-11-03 Yuli Xie Fused ring compound as wee-1 inhibitor, and preparation method therefor and use thereof
US12161722B2 (en) 2021-06-25 2024-12-10 Korea Research Institute Of Chemical Technology Bifunctional heterocyclic compound having BTK degradation function via ubiquitin proteasome pathway, and use thereof
CN116462687B (zh) 2022-01-18 2025-01-07 江苏天士力帝益药业有限公司 Wee1抑制剂及其制备和用途
CN116836184B (zh) * 2022-03-25 2025-07-25 药雅科技(上海)有限公司 Wee1激酶抑制剂的制备及其应用
WO2023217201A2 (zh) * 2022-05-10 2023-11-16 杭州德睿智药科技有限公司 作为Wee1抑制剂的新型嘧啶并杂环类新化合物及其应用
CN117402162A (zh) 2022-07-13 2024-01-16 江苏天士力帝益药业有限公司 Wee1抑制剂及其制备和用途
TW202519226A (zh) 2023-11-08 2025-05-16 美商艾克塞里克斯公司 使用抑制pkmyt1之化合物治療癌症之方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7504396B2 (en) 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
EP1727819A1 (en) 2004-03-15 2006-12-06 F.Hoffmann-La Roche Ag Novel dichloro-phenyl-pyrido¬2,3-d|pyrimidine derivatives, their manufacture and use as pharmaceutical agents
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
PE20080695A1 (es) 2006-04-27 2008-06-28 Banyu Pharma Co Ltd Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
JP5411847B2 (ja) 2007-04-25 2014-02-12 Msd株式会社 Weelキナーゼインヒビターとしてのジヒドロピラゾロピリミジノン誘導体の多形
MX2009013728A (es) 2007-06-15 2010-01-25 Banyu Pharma Co Ltd Derivados de bicicloanilina.
WO2009054332A1 (ja) * 2007-10-23 2009-04-30 Banyu Pharmaceutical Co., Ltd. ピリドン置換ジヒドロピラゾロピリミジノン誘導体
EP2376493B1 (en) * 2008-12-12 2016-10-05 Msd K.K. Dihydropyrimidopyrimidine derivative
US8575179B2 (en) 2008-12-12 2013-11-05 Msd K.K. Dihydropyrazolopyrimidinone derivatives
AU2011340690C1 (en) * 2010-12-06 2016-03-10 Glaxo Group Limited Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by Lp - PLA2
AR084515A1 (es) * 2010-12-22 2013-05-22 Merz Pharma Gmbh & Co Kgaa Derivados heterociclicos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades asociadas al sistema nervioso central tales como parkinson y alzheimer, entre otras
TWI532742B (zh) * 2011-02-28 2016-05-11 艾伯維有限公司 激酶之三環抑制劑
JP2014520855A (ja) 2011-07-15 2014-08-25 アッヴィ・インコーポレイテッド 増殖性疾患の治療に有用な三環式キナーゼ阻害薬
WO2013013031A1 (en) * 2011-07-19 2013-01-24 Abbvie Inc. Pyridazino [4, 5 -d] pyrimidin- (6h) -one inhibitors of wee - 1 kinase
US9181239B2 (en) 2011-10-20 2015-11-10 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
JP2015511245A (ja) 2012-02-23 2015-04-16 アッヴィ・インコーポレイテッド ピリドピリミジノン系キナーゼ阻害薬
CN102816164A (zh) * 2012-08-31 2012-12-12 北京理工大学 一种合成7-氨基-2,3-二氢嘧啶[4,5-d]嘧啶-4(1H)-酮的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARTIN, MATTHEW W., ET AL., STRUCTURE-BASED DESIGN OF NOVEL 2-AMINO-6-PHENYL-PYRIMIDO [5?, 4?: 5, 6] PYRIMIDO [1, 2-A] BENZIMIDAZOL-5 (6 H)-ONES AS POTENT AND ORALLY ACTIVE INHIBITORS OF LYMPHOCYTE SPECIFIC KINASE (LCK): SYNTHESIS, SAR, AND IN VIVO ANTI-INFLAMMATORY ACTIVITY., 16 February 2008 (2008-02-16) *

Also Published As

Publication number Publication date
EP3083625A1 (en) 2016-10-26
AU2014369457B2 (en) 2018-08-09
BR112016014151B1 (pt) 2023-01-17
NO3083625T3 (enExample) 2018-03-31
GB201322602D0 (en) 2014-02-05
LT3083625T (lt) 2017-12-27
CY1120035T1 (el) 2018-12-12
KR20160098499A (ko) 2016-08-18
RU2016123363A (ru) 2018-01-25
CN105829315B (zh) 2019-03-08
KR102405462B1 (ko) 2022-06-03
IL245672A0 (en) 2016-06-30
PT3083625T (pt) 2018-02-06
AU2014369457A1 (en) 2016-06-09
CA2933755C (en) 2023-01-31
BR112016014151A2 (enExample) 2017-08-08
CA2933755A1 (en) 2015-06-25
MX371108B (es) 2020-01-17
HUE037908T2 (hu) 2018-09-28
SMT201800020T1 (it) 2018-05-02
JP2017500335A (ja) 2017-01-05
RU2691105C1 (ru) 2019-06-11
US9850247B2 (en) 2017-12-26
DK3083625T3 (en) 2017-12-18
JP6437559B2 (ja) 2018-12-12
PL3083625T3 (pl) 2018-03-30
US20160318936A1 (en) 2016-11-03
NZ720178A (en) 2022-05-27
ES2650013T3 (es) 2018-01-16
SG11201603814TA (en) 2016-07-28
MX2016007801A (es) 2016-09-07
SI3083625T1 (en) 2018-03-30
EP3083625B1 (en) 2017-11-01
ZA201603337B (en) 2018-07-25
WO2015092431A1 (en) 2015-06-25
RS56731B1 (sr) 2018-03-30
CN105829315A (zh) 2016-08-03
HRP20180080T1 (hr) 2018-03-09

Similar Documents

Publication Publication Date Title
CY2024003I1 (el) Ενωσεις χρησιμες ως αναστολεις κινασης
IL245672B (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
LT3303334T (lt) Tirozinkinazės inhibitoriai
DK3319956T3 (da) Substituerede oxopyridinderivater
LT3057586T (lt) Bromodomeno inhibitoriai
DK3298002T3 (da) Heterocykliske amider som kinasehæmmere
EP2969007A4 (en) HISTONE DEMETHYLASE INHIBITORS
LT3080100T (lt) Lizinui specifinės demetilazės-1 inhibitoriai
DK3323269T3 (da) Målingsbaseret direkte adgangskonfiguration
AR095266A1 (es) Inhibidores de bromodominios tetraciclicos
HUE053215T2 (hu) Heterociklusos amidok kináz inhibitorokként
EP3985003C0 (en) DNA-PK INHIBITORS
HRP20181129T1 (hr) Pirimidin inhibitori fgfr4
DK2950760T4 (da) Stomiudstyr
EP3767151C0 (en) FURNITURE LEVELING DEVICE
SMT201700363T1 (it) Inibitori di bromodominio cristallini
DK3004666T3 (da) Skrue
HUE050842T2 (hu) Janus-kináz inhibitor
EP2975063A4 (en) LOW SUBSTITUTED CELLULOSE ACETATE
IL246054B (en) Tropomyosin-related kinase (trk) inhibitors
DK2986611T3 (da) Bestemte proteinkinaseinhibitorer
HRP20171890T1 (hr) Supstituirani imidazopiridazini
DK3058044T3 (da) Kølemiddel
DK2843146T3 (da) Vægblok-element
MA44607A (fr) Inhibiteurs de kinase